European Urology Oncology

Slides:



Advertisements
Similar presentations
Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly  Brent K. Hollenbeck, Samuel R. Kaufman, Phyllis.
Advertisements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 58, Issue 4, Pages (October 2010)
Volume 61, Issue 6, Pages (June 2012)
Volume 53, Issue 4, Pages (April 2008)
European Urology Oncology
Volume 71, Issue 1, Pages (January 2017)
The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients 
Volume 60, Issue 5, Pages (November 2011)
Volume 53, Issue 5, Pages (May 2008)
Volume 70, Issue 5, Pages (November 2016)
Yair Lotan, Peter C. Black, Laura Caba, Sam S. Chang, Michael S
Volume 181, Issue 4, Pages (April 2009)
Prostate Cancer Epidemic in Sight?
Volume 72, Issue 5, Pages (November 2017)
European Urology Oncology
European Urology Oncology
Back to the Future: Introduction and Conclusions
European Urology Oncology
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients  Timo F.W. Soeterik,
Prostate Cancer Epidemic in Sight?
Stephen B. Williams, Ashish M
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases  Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Volume 53, Issue 4, Pages (April 2008)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Richard C. Harkaway  European Urology Supplements 
Volume 50, Issue 5, Pages (November 2006)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
European Urology Oncology
European Urology Oncology
Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study  Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,
European Urology Oncology
European Urology Oncology
Neal Shore  European Urology Supplements 
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review  Alexey Surov, Hans Jonas Meyer, Andreas.
Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis  Joseph Sargon Joseph, Vincent.
The Cost to Medicare of Bladder Cancer Care
Volume 75, Issue 5, Pages (May 2019)
European Urology Oncology
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy  Neal Patel, Eliza Cricco-Lizza,
European Urology Oncology
European Urology Oncology
European Urology Oncology
Counselling of the Prostate Cancer Patient as a Whole Person
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Proportion of continuous, intermittent, and limited (
European Urology Oncology
European Urology Oncology
Salvage Local Treatments After Focal Therapy for Prostate Cancer
European Urology Oncology
European Urology Oncology
European Urology Oncology
European Urology Oncology
European Urology Oncology
European Urology Oncology
Maximilian Burger, Ashish M. Kamat, David McConkey 
How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?  Shahrokh Shariat, Paolo Gontero, James.
Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood  Jan F.M. Verbeek,
Presentation transcript:

European Urology Oncology Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists  Simon P. Kim, Nilay D. Shah, Neal J. Meropol, Jon C. Tilburt, Paul L. Nguyen, James B. Yu, Robert Abouassaly, Albert Kim, Cary P. Gross  European Urology Oncology  DOI: 10.1016/j.euo.2018.08.004 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 (A) Respondents’ perceptions of the effectiveness of and comfort with routinely recommending active surveillance (AS) for intermediate-risk prostate cancer by specialty (p<0.001 for comfortable recommending AS). (B) Self-reported proportion of patients undergoing active surveillance among patients diagnosed with intermediate-risk prostate cancer (all p<0.001). RO=radiation oncologist; URO=urologist. European Urology Oncology DOI: (10.1016/j.euo.2018.08.004) Copyright © 2018 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.